GLP-1 drugs are genuinely one of the most significant medical developments in decades. I want to give you a fair read on them — which means being honest about both the evidence and the gaps.

What GLP-1 means

GLP-1 stands for glucagon-like peptide-1. It’s a hormone your small intestine naturally produces after you eat. It does several things:

  1. Signals your pancreas to release insulin (which lowers blood sugar)
  2. Signals your pancreas to slow down glucagon release (which raises blood sugar)
  3. Slows stomach emptying, so food moves through you more gradually
  4. Signals your brain’s appetite centers that you’re full

The GLP-1 drugs — semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — mimic or amplify this hormone. They work by binding to the same receptors your natural GLP-1 binds to, but they’re engineered to stay active much longer. Natural GLP-1 lasts only 1–2 minutes. Semaglutide lasts about a week.

What the clinical trials actually showed

Semaglutide (Wegovy) for weight loss: In the STEP 1 trial (2021), 1,961 adults with obesity but no diabetes took 2.4mg semaglutide weekly for 68 weeks. Average weight loss: 14.9% of body weight, compared to 2.4% in the placebo group. That’s roughly 35 pounds on a 235-pound person.

Tirzepatide (Zepbound) for weight loss: In the SURMOUNT-1 trial (2022), participants lost up to 22.5% of body weight at the highest dose — the largest effect size ever seen in a pharmacological weight loss trial.

These are genuinely large numbers. The drugs work.

What happens when you stop

This is the part most news coverage skips.

In a 2022 follow-up study published in Diabetes, Obesity and Metabolism, participants who stopped semaglutide after 68 weeks regained, on average, two-thirds of the weight they’d lost within one year. Blood pressure, cholesterol, and blood sugar markers mostly returned to their pre-drug levels.

This doesn’t mean the drugs are useless — it means they appear to require ongoing use for sustained effect, similar to how blood pressure medication only works while you take it.

The implication: for most people, this is a long-term commitment, not a 6-month reset.

The side effects you should know about

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These affect 30–50% of users and are most common when doses are increased. They tend to improve over time for most people, but not all.

The rarer but more serious concerns:

  • Gastroparesis: delayed stomach emptying that persists after stopping the drug, in some patients
  • Pancreatitis: rare, but risk appears elevated; don’t use if you have a personal or family history of medullary thyroid cancer or MEN2 syndrome
  • Muscle loss: rapid weight loss from any cause can include muscle mass; resistance training while on these drugs appears protective

Who these drugs are (and aren’t) for

The clinical trials primarily enrolled people with BMI ≥ 30 (or ≥ 27 with a weight-related health condition). That’s the population where the data is strongest.

They’re not approved for general weight management in people without those criteria. Off-label prescribing happens, but the risk-benefit calculation looks different.

For people with type 2 diabetes or prediabetes plus significant obesity: the evidence is compelling, and the cardiovascular outcomes data for semaglutide (the SELECT trial) shows real heart protection benefits. For someone wanting to lose 15 pounds who is otherwise healthy: much harder to justify.

The telehealth angle

Compounded semaglutide and tirzepatide became widely available through telehealth platforms when brand-name drugs were on the FDA shortage list. As of late 2026, that status is changing — tirzepatide was removed from the shortage list in 2024, and semaglutide’s status has evolved.

This matters because FDA shortage-list status determines whether compounding pharmacies can legally produce these compounds. If you’re using a telehealth platform for compounded GLP-1s, verify that the program is legally operating given current FDA guidance.

I maintain a comparison page for the programs I’ve vetted here.

Questions worth asking your doctor

If you’re considering these medications:

  1. What’s the realistic target — weight, A1C, or both?
  2. How long do you expect me to stay on it?
  3. What monitoring will we do (thyroid, pancreatic enzymes)?
  4. If I lose weight and then stop, what’s the plan?

This content is for educational purposes only and is not medical advice. GLP-1 medications require a prescription and medical evaluation. Do not start or stop any prescription medication without consulting your healthcare provider.